These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8744561)

  • 21. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
    Durbin AP; Whitehead SS; McArthur J; Perreault JR; Blaney JE; Thumar B; Murphy BR; Karron RA
    J Infect Dis; 2005 Mar; 191(5):710-8. PubMed ID: 15688284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination.
    Green S; Kurane I; Edelman R; Tacket CO; Eckels KH; Vaughn DW; Hoke CH; Ennis FA
    J Virol; 1993 Oct; 67(10):5962-7. PubMed ID: 8371350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine.
    Rothman AL; Kanesa-thasan N; West K; Janus J; Saluzzo JF; Ennis FA
    Vaccine; 2001 Sep; 19(32):4694-9. PubMed ID: 11535318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atypical antibody responses in dengue vaccine recipients.
    Kanesa-Thasan N; Sun W; Ludwig GV; Rossi C; Putnak JR; Mangiafico JA; Innis BL; Edelman R
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):32-8. PubMed ID: 14740953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.
    Huang CY; Butrapet S; Pierro DJ; Chang GJ; Hunt AR; Bhamarapravati N; Gubler DJ; Kinney RM
    J Virol; 2000 Apr; 74(7):3020-8. PubMed ID: 10708416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.
    Simasathien S; Thomas SJ; Watanaveeradej V; Nisalak A; Barberousse C; Innis BL; Sun W; Putnak JR; Eckels KH; Hutagalung Y; Gibbons RV; Zhang C; De La Barrera R; Jarman RG; Chawachalasai W; Mammen MP
    Am J Trop Med Hyg; 2008 Mar; 78(3):426-33. PubMed ID: 18337339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines.
    Velzing J; Groen J; Drouet MT; van Amerongen G; Copra C; Osterhaus AD; Deubel V
    Vaccine; 1999 Mar; 17(11-12):1312-20. PubMed ID: 10195766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
    Durbin AP; Karron RA; Sun W; Vaughn DW; Reynolds MJ; Perreault JR; Thumar B; Men R; Lai CJ; Elkins WR; Chanock RM; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2001 Nov; 65(5):405-13. PubMed ID: 11716091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells.
    Eckels KH; Scott RM; Bancroft WH; Brown J; Dubois DR; Summers PL; Russell PK; Halstead SB
    Am J Trop Med Hyg; 1984 Jul; 33(4):684-9. PubMed ID: 6476216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Live attenuated tetravalent dengue vaccine.
    Bhamarapravati N; Sutee Y
    Vaccine; 2000 May; 18 Suppl 2():44-7. PubMed ID: 10821973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
    Robert Putnak J; Coller BA; Voss G; Vaughn DW; Clements D; Peters I; Bignami G; Houng HS; Chen RC; Barvir DA; Seriwatana J; Cayphas S; Garçon N; Gheysen D; Kanesa-Thasan N; McDonell M; Humphreys T; Eckels KH; Prieels JP; Innis BL
    Vaccine; 2005 Aug; 23(35):4442-52. PubMed ID: 16005749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. I. Pre-clinical studies.
    Marchette NJ; Dubois DR; Larsen LK; Summers PL; Kraiselburd EG; Gubler DJ; Eckels KH
    Am J Trop Med Hyg; 1990 Aug; 43(2):212-8. PubMed ID: 1975159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines.
    Gwinn W; Sun W; Innis BL; Caudill J; King AD
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):39-47. PubMed ID: 14740954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.
    McArthur JH; Durbin AP; Marron JA; Wanionek KA; Thumar B; Pierro DJ; Schmidt AC; Blaney JE; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2008 Nov; 79(5):678-84. PubMed ID: 18981503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
    Kanesa-thasan N; Smucny JJ; Hoke CH; Marks DH; Konishi E; Kurane I; Tang DB; Vaughn DW; Mason PW; Shope RE
    Vaccine; 2000 Oct; 19(4-5):483-91. PubMed ID: 11027812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine.
    Dharakul T; Kurane I; Bhamarapravati N; Yoksan S; Vaughn DW; Hoke CH; Ennis FA
    J Infect Dis; 1994 Jul; 170(1):27-33. PubMed ID: 7912253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dengue virus vaccine studies in Puerto Rico: a review.
    Kraiselburd E
    P R Health Sci J; 1987 Apr; 6(1):27-9. PubMed ID: 3615798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of viraemia and limited antibody response of dengue virus immune rhesus monkeys after vaccination with DEN-2/S-1 vaccine.
    Kraiselburd E; Kessler MJ; Torres-Blasini G
    Trans R Soc Trop Med Hyg; 1984; 78(4):445-8. PubMed ID: 6548325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis.
    Angsubhakorn S; Yoksan S; Pradermwong A; Nitatpattana N; Sahaphong S; Bhamarapravati N
    Southeast Asian J Trop Med Public Health; 1994 Sep; 25(3):554-9. PubMed ID: 7777925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.